SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Dave O.10/15/2009 12:26:32 PM
   of 7143
 
A stock I've traded for years is SVNT.

Fly on the Wall had this earlier today:

Amgen (AMGN) is rumored to be interested in Savient Pharmaceuticals (SVNT) for $30 per share. Savient has been the subject of takeout chatter in the past. In September, Leerink Swann, which rates the stock a Buy, said the company's increasing focus on cost containment following workforce reductions increases the likelihood that it will get acquired upon approval of Krystexxa.

So if you're a gambler theoretically you could make 100% if the "rumor" materializes.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News